Tag Archive for: semaglutide

The company teased data for efinopegdutide, a GLP-1/glucagon receptor co-agonist, in nonalcoholic steatohepatitis compared to Novo Nordisk’s semaglutide, which is not yet approved for NASH.

The FDA has warned that drug compounders are selling products that falsely claim to contain semaglutide, the same active ingredient as Novo Nordisk’s blockbuster diabetes and obesity drugs Ozempic and Wegovy their oral sibling Rybelsus.

Novo Nordisk and Pfizer separately released data on Monday showing that pills from the same class as Novo’s increasingly popular weight loss drugs such as Wegovy are about as effective as those injected medicines, giving shares of both companies a boost.

Novo Nordisk expects the oral version of its semaglutide drug to treat obesity to have similar efficacy as its Wegovy injection, with data from a late-stage clinical trial due before the end of June, a senior executive said on Thursday.

Diabetes and obesity drug developer Novo Nordisk on Thursday significantly raised its full-year operating profit and sales expectations on the back of strong demand for its highly popular Wegovy obesity drug.

The drugmaker stated that the Committee for Medicinal Products for Human Use’s (CHMP) positive opinion was an “important recognition of the unmet medical need among adolescents living with obesity and the need for additional treatment options”.

Patients discontinuing the use of weight-loss drugs such as Wegovy risk regaining their original body weight in about five years, a company official said on Wednesday.

The company’s highly anticipated weight loss medicine, Wegovy, will soon be made available to thousands of people in the UK.

Amgen Inc.’s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday.

The benefits of obesity drugs such as Novo Nordisk’s Wegovy on healthcare systems in countries such as the United States are so significant that the expected entry of rival drugs will not hurt its margins, CEO Lars Jorgensen told Reuters on Tuesday.